BostonGene has won three awards in the 2024 Clinical Trials Arena Excellence Awards in the Innovation, Product Launches and Marketing categories, demonstrating again the company’s commitment to revolutionizing cancer care.
The Clinical Trials Arena Excellence Awards celebrate the greatest achievements and innovations in the pharmaceutical industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies that are driving change in the industry.
Go deeper with GlobalData
BostonGene received the Innovation award for its Immune System Profiling Platform and Clinical Pathway Navigator, which are transforming minimally invasive immune profiling and aligning NCCN Guidelines® with molecular testing to enhance personalized oncology treatments. The company also won the Product Launches award for its artificial intelligence (AI)-driven digital pathology platform and the Unknown Primary test, advancing clinical diagnostics and the personalization of cancer therapies. Additionally, BostonGene earned the Marketing award for its informative and engaging website, which effectively communicates updates and resources about its AI-powered multiomics platform.
“We are deeply honored to be recognized with three 2024 Clinical Trials Arena Excellence Awards, acknowledging our contributions to precision medicine and clinical diagnostics. These awards are a testament to the innovative spirit at BostonGene as we lead the way in advancing precision medicine. Our work equips clinicians with the tools to make more informed decisions, ultimately enhancing patient care and outcomes.” – Joe Lennerz, MD, PhD, Chief Scientific Officer, BostonGene.
Precision medicine: Advancing personalized cancer therapy with innovative platforms
BostonGene’s innovation award in precision medicine is attributed to the transformative impact of its Immune System Profiling Platform and Clinical Pathway Navigator. The Immune System Profiling Platform is a minimally invasive blood test that provides a comprehensive analysis of the patient’s immune system, reducing the need for recurrent tissue biopsies. Leveraging a machine-learning algorithm trained on an extensive dataset, the platform accurately identifies immune activation states, providing insight into the critical role of immunity in the treatment of cancer.
The Clinical Pathway Navigator tool integrates the latest NCCN Guidelines® with findings from advanced molecular testing, equipping oncologists with data-driven results to make informed treatment decisions. The tool addresses critical challenges posed by the rapid evolution of clinical guidelines and the growing number of genetic biomarkers. By designing personalized treatment plans based on each patient’s unique biological and clinical profile, the Clinical Pathway Navigator supports precision medicine across more than 40 cancer types.
BostonGene’s innovation extends beyond the technical excellence of its proprietary AI algorithms and tools— it lies in the practical application of these technologies to address the urgent needs of both oncologists and patients. By providing rapid and accurate immune system profiling with a sophisticated clinical support tool, BostonGene streamlines oncologists’ workflows while paving the way for more personalized and effective cancer care. These innovations have the potential to significantly impact the future of clinical trials and patient stratification, driving advancements in precision medicine.
Product launches: Setting new standards in clinical diagnostics with AI
BostonGene’s award for product launches highlights the impact of its AI-based digital pathology platform and the Unknown Cancer Primary test. The platform standardizes tissue analysis and minimizes human error, advancing patient management with methods including IHC and MxIF. It helps provide high accuracy in identifying biomarkers and predicting subsequent therapy responses. The platform enhances the efficiency of pathologists’ workflows with integrated solutions that offer comprehensive diagnostic services and high-powered precision analytics.
The Unknown Primary test addresses a critical challenge in oncology— diagnosing a metastatic cancer with an unknown origin. The test plays a pivotal role in informing treatment decisions by equipping pathologists and cancer care teams with a definitive diagnosis. BostonGene’s Tumor Portrait™ test further supports personalized treatment strategies by providing an in-depth analysis of a patient’s biomarkers, tumor biology, and immune profile. The technical excellence demonstrated by the proprietary AI algorithms and tools, which outperform other available technologies in accuracy and predictive capabilities, is a testament to BostonGene’s innovation in product development.
BostonGene’s commitment to advancing pathology is further evident with its focus on building and leveraging large data cohorts for sophisticated analyses and discovery. The company’s innovative approaches are supported by publications in high-impact scientific journals and conference abstracts, highlighting the predictive power of its AI-based analyses for survival outcomes in cancer patients.
Digital innovation: Enhancing patient engagement and education through technology
In a significant stride toward enhancing its digital presence, BostonGene launched its new website in the summer of 2023, strategically designed to meet the needs of patients, healthcare providers and researchers. The website emphasizes BostonGene’s cutting-edge clinical and discovery solutions, offering comprehensive insights into AI-driven molecular and immune profiling technologies like Tumor Portrait™, Liquid Biopsy, Immunoprofiling and Spatial Proteomics tests.
The website’s robust technology and solutions section offers an in-depth exploration of BostonGene’s cloud-based software platform, bioinformatics capabilities and advanced next-generation sequencing (NGS) tools. These technologies are pivotal in supporting care teams in identifying personalized treatment strategies with greater accuracy and efficacy.
BostonGene’s dedication to education and support is reflected in the comprehensive resources available for patients, caregivers, and providers. The website features patient stories and detailed information about laboratory and bioinformatics services, highlighting the tangible benefits of BostonGene’s molecular testing and its integrative approach to supporting patient care.
Recognizing the financial barriers that patients may face, BostonGene provides a robust Financial Assistance Program. This patient-centric approach fosters trust and ensures that cutting-edge diagnostic tests remain accessible to those in need, reinforcing the company’s commitment to equitable healthcare.
The website’s dynamic News and Events section and engaging video content keep visitors informed about the latest advancements and educational materials. This is complemented by a strategic press release schedule highlighting key developments, including participation in major conferences and significant research publications, solidifying BostonGene’s position as a pioneer in developing AI-based healthcare solutions.
BostonGene’s social media strategy has significantly amplified its digital presence, with LinkedIn followers growing by an impressive 107.1% over the past year. Active engagement on X (formerly Twitter) resonates with the healthcare and scientific community, sharing timely updates and insights that underscore BostonGene’s leadership in advancing cancer treatment strategies.
The company’s email marketing campaigns, executed through MailChimp, have demonstrated BostonGene’s expertise in content delivery and audience engagement, boasting high open and click-through rates. These campaigns illustrate the company’s commitment to maintaining strong connections with its stakeholders, ensuring consistent and valuable communications that keep them informed and engaged.
Company Profile
BostonGene is a biotechnology company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continuously pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients’ molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that propel precision medicine and advance oncology research.
Contact Details
University Office Park III
95 Sawyer Road, Suite 500
Waltham, MA 02453
Links
Website: https://bostongene.com/
